Lipoxin analogs as novel inhibitors of angiogenesis
US8722654B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | May 12, 2011 |
| Grant date | May 13, 2014 |
| Priority date | — |
| Expiry date | Sep 4, 2031 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07C57/42
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention is generally drawn to novel isolated therapeutic agents, termed lipoxins, generated from the interaction between a dietary omega-6 polyunsaturated fatty acid (PUFA) such as arachidonic acid (AA), oxygenases and the analgesic aspirin (ASA). Surprisingly, careful isolation of compounds generated from the combination of components in an appropriate environment provide di- and tri-hydroxy containing derivatives of AA containing compounds having unique structural and physiological properties. The present invention therefore provides for many new useful therapeutic di- and tri-hydroxy derivatives of AA (lipoxins, aspirin-triggered epi-lipoxins) that diminish, prevent, or eliminate NV, hemangiogenesis and/or angiogenic condition(s) of corneal tissue. The present invention also provides methods of use, methods of preparation, and packaged pharmaceuticals for use as medicaments for the compounds disclosed throughout the specification.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.